TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fluid intake per kilogram of body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma volume maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epinephrine plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gastric emptying (GE) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antral contractile activity (ACF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AMP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: High-density lipoprotein 2 cholesterol (HDL(2)-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: minimum meal frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: minimum dietary diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decline in distressing behavioral symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caregiver confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite outcome of death or readmission for acute myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Neurodevelopment outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CSF NSE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: S-100 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression to CDR = 0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decline in memory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Orthostatic tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Investigator's Global Assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute claudication distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for MVET at 7 days of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of MVET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical bronchopulmonary dysplasia (BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper gastrointestinal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Hegar measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum platelet‐derived growth factor (PDGF) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: transforming growth factor beta (TGFbeta) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total growth factor activity of serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed-Up and Go test times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility on functional tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antirotavirus IgA seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine efficacy against any rotavirus gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vaccine efficacy against severe rotavirus gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: cigarette use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no heavy drinking days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCV RNA load increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maxillary canine eruption pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRC sum score at ICU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean inhibition of total platelet deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean inhibition of fibrin deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of endoleak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incision healing delay
Endpoint domain: Adverse events/effects
Primary endpoint: Energy level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Attractiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Miniscrew stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttrial incidence of BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Posttrial incidence of Lactobacillus colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete block at 15 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in psychological symptom dimensions (SCL-90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repetition of suicide attempts
Endpoint domain: Adverse events/effects
Primary endpoint: AHI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-h post-load plasma glucose value ≥155mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin secretion and hyperbolic product (BxS) on HOMA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Bone fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: serum 25(OH)D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Partial clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of nicotine dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average visual field extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tear evaporation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nelson grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of coagulase-negative staphylococci (CoNS) colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Propionibacterium acnes colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 24 h urinary protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: red blood cell count of urinary sediment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cardiac death/nonfatal acute MI
Endpoint domain: Mortality/survival
Primary endpoint: Development of lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: Weight loss of at least 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating NGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antidrug antibodies in serum
Endpoint domain: Adverse events/effects
Primary endpoint: Mild, transient ocular AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of women on sick leave due to lumbopelvic pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24h urinary excretion of total flavonoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GFR at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Graft survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Mean E* value between reference tooth and crown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total pathologic complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraoperative time within target glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Within-patient glucose variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gray matter reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: B cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma concentrations of 8‐hydroxy‐2‐deoxy‐guanosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optic nerve cup shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate of calves
Endpoint domain: Mortality/survival
Primary endpoint: Partial pressure of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seven-day point-prevalence abstinence from smoking at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heavy episodic drinking occasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of late-onset sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Days to discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cycles to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failure loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) on the femur neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ox-LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma antioxidant activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatal and nonfatal myocardial infarction and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Patient satisfaction with remote programming
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of severe embolism episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pro-inflammatory cytokines (IL-6 and TNF-α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fascial closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: continued resolution of clinical signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of sertraline in treating major depressive disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient satisfaction with temperature
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial responses to pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desaturation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma BC concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma VE concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue concentration of BC in normal colonic mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recurrent diverticulitis necessitating readmission to hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: SNR of the aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of therapeutic relationship
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in gapping of zygapophysial joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: alanine aminotransferase normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month ODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary sodium recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary nitrogen recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TS excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall muscle strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-min walk test (6-MWT) distance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total IDeg exposure (AUCIDeg,0‐120h,SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration (C max,IDeg,SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose-lowering effect (AUCGIR,0‐24h,SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients receiving a change in therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interrater reliability for angulation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in clinical fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fractures outcomes
Primary endpoint: Increase in BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in radiographic vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fractures outcomes
Primary endpoint: Mean insulin requirements for high-protein meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diabetes medication adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of follow-up visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stabilization or improvement of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher scotopic activity of treated patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Short Form‐36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rhinosinusitis Outcome Measure‐31
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma glucose levels after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin levels at the beginning of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total paired VAS score differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum QTcB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Requirement for rescue analgesic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Onset time of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of daily living (ADL) HOS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sports HOS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient subjective outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction in fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all-cause mortality reduction
Endpoint domain: Mortality/survival
Primary endpoint: Complete responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of additional procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retained stones
Endpoint domain: Adverse events/effects
Primary endpoint: Dose reductions due to leukopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Received dose-intensity (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: child social‐emotional functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sleep problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of bacterial overgrowth syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lower psychopathological scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decisional Conflict Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction With Decision Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Myeloperoxidase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery rate after 12 months
Endpoint domain: Mortality/survival
Primary endpoint: serum sex-hormone binding globulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: dysmenorrhea duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Disease Progression (TTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol expectancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brand choice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degrees of sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degrees of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical response maintained through week 54
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission at weeks 30 and 54
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal healing at weeks 30 and 54
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PPI use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD health-related quality of life heartburn score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of patients not undergoing re-treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: markers of macrovascular disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: radial pulse change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: β‐endorphin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CSFQ‐14 total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum inflammatory factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DAI values reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal appearance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective need for recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status